CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...

2seventy bio (NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M net of ...

Cambridge drugmaker 2seventy bio has agreed to be acquired by Bristol Myers Squibb for approximately $286 million in cash. Bristol Myers Squibb (NYSE: BMY) has been partnering with 2seventy to ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

CAMBRIDGE, Mass., March 11, 2025--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb ...

It was revealed Monday that Pharma giant Bristol-Myers Squibb will acquire all outstanding shares of 2seventy bio for $5, valuing the deal at ~$286m. 2seventy bio, a Cambridge-based biotech ...

Bristol Myers Squibb is acquiring 2seventy Bio for $5.00 per share, which is an 88% premium. The $286 million all-cash deal is expected to close in Q2 2025. The ‘Trade of the Day’ is now live.

2seventy bio Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all of the outstanding shares of 2seventy bio in an all-cash transaction for a price of ...

2seventy bio, the cell therapy spinout of Bluebird bio, is selling itself to Bristol Myers Squibb after losing most of its market value in its short run as an independent biotechnology company. Per ...

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...